Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinib

Abstract excerpt

Gefitinib exhibits very limited efficacy in gastric cancer (GC). Indeed, the limited clinical results obtained with gefitinib alone justify investigation of additional therapeutic strategies. Here, we demonstrate the importance of EGFR and HER2 in GC malignancy using RNA interference (RNAi). Additionally, we explored the ability of RNAi targeting EGFR and HER2 to enhance the sensitivity of GC cells to gefitinib....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to HER2/EGFR in Cancer Research
• Share to Monoclonal and Polyclonal Antibodies Research